Press release
Segment Evaluation and Major Growth Areas in the Tumor Necrosis Factor Inhibitor Drugs Market
Tumor Necrosis Factor Inhibitor Drugs Market
Projected Market Growth and Expansion of the Tumor Necrosis Factor Inhibitor Drugs Market
The tumor necrosis factor inhibitor drugs market is anticipated to reach a value of $48.58 billion by 2030, growing at a compound annual growth rate (CAGR) of 2.8%. This steady rise is supported by factors such as the increasing availability of biosimilars, progress in precision medicine, a growing number of chronic disease patients, adoption of digital health monitoring technologies, and advancements in novel drug delivery systems. Upcoming trends expected to influence the market include personalized TNF inhibitor treatments, wider biosimilar uptake, combination therapies involving TNF inhibitors, the shift toward home-based and self-administered care, and the development of sophisticated drug delivery methods.
Download a free sample of the tumor necrosis factor inhibitor drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9383&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Driving the Tumor Necrosis Factor Inhibitor Drugs Market
The tumor necrosis factor inhibitor drugs market features a range of prominent players, including AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., Novartis International AG, Pfizer Inc., Samsung Bioepis Co. Ltd., Sanofi SA, Lupin Ltd., Cadila Healthcare Ltd., Aryogen Biopharma, Casi Pharmaceuticals, Celltrion Inc., Hanall Biopharma, Intas Pharmaceuticals, Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Boehringer Ingelheim GmbH, Merck KGaA, and Teva Pharmaceutical Industries Limited.
A notable recent development occurred in September 2024 when Tharimmune, a US-based biopharmaceutical company specializing in autoimmune and inflammatory diseases, entered into a partnership with Intract Pharma. This collaboration aims to develop targeted oral delivery systems for biologic TNF-inhibitor therapies, transitioning the traditionally injectable drugs into convenient oral pill formats. Intract Pharma brings its proprietary Soteria platform to enable oral administration of large-molecule biologics such as monoclonal antibodies.
Key Trends Shaping the Tumor Necrosis Factor Inhibitor Drugs Market
Pharmaceutical companies in the TNF inhibitor space are increasingly focusing on creating innovative biosimilar products that are interchangeable with existing branded therapies. These biosimilars provide comparable safety, efficacy, and purity while offering more affordable and accessible treatment alternatives. This approach helps expand patient access and drives competition in the biologics market.
For example, in May 2024, Teva Pharmaceuticals partnered with Luxembourg-based biotech firm Alvotech to launch SIMLANDI (adalimumab-ryvk) injection in the U.S. This product is an interchangeable biosimilar to Humira and is approved for treating a broad range of autoimmune diseases, including adult rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
View the full tumor necrosis factor inhibitor drugs market report:
https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Market Segments Holding the Largest Share in the Tumor Necrosis Factor Inhibitor Drugs Market
This report segments the tumor necrosis factor inhibitor drugs market as follows:
By Product Type: Humira, Enbrel, Remicade, Simponi or Simponi Aria, Cimzia, and Biosimilars
By Route of Administration: Subcutaneous Injection and Intravenous Injection
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
By Application: Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, and Other Applications
These segments illustrate the diversity of products, delivery methods, distribution networks, and therapeutic uses that are central to the tumor necrosis factor inhibitor drugs market landscape.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Segment Evaluation and Major Growth Areas in the Tumor Necrosis Factor Inhibitor Drugs Market here
News-ID: 4501459 • Views: …
More Releases from The Business Research Company
Segmentation, Major Trends, and Competitive Overview of the Vitamin and Minerals …
The vitamin and minerals market is set for significant expansion in the coming years, driven by a variety of factors ranging from evolving consumer lifestyles to technological advancements in supplement delivery. As awareness around health and wellness continues to grow globally, this industry is positioned to experience robust growth and innovation. Let's explore the current market size, key players, emerging trends, and segmentation in detail.
Projected Market Size and Growth Drivers…
Trends in Growth, Market Segmentation, and Competitive Strategies Influencing th …
The rhinovirus infections drug market is poised for significant expansion over the coming years, driven by advancements in antiviral therapies and growing awareness about respiratory illnesses. This sector is evolving rapidly, with innovative treatment options and a focus on improving patient outcomes. Below, we explore the market's expected growth, key players, emerging trends, and detailed segment analysis.
Market Growth Outlook for Rhinovirus Infections Drug Market
The rhinovirus infections drug market…
Leading Companies Enhancing Their Presence in the Viral Vectors and Plasmid DNA …
The viral vectors and plasmid DNA industry is on the brink of significant expansion, driven by advances in gene therapy and immunotherapy. This market is set to witness robust growth fueled by technological innovations and increasing demand across various medical applications. Let's explore the current market size, key players, prevailing trends, and important market segments shaping the future of this dynamic field.
Projected Market Size and Growth Trajectory for Viral Vectors…
Analysis of Market Segmentation, Major Trends, and the Competitive Environment i …
The retinal biologics sector is on track for significant expansion, driven by innovations and growing demand in ophthalmic care. With new treatments emerging and infrastructure improving globally, this market is set for rapid growth. Below, we explore the market size projections, key players, emerging trends, and segmentation that define this promising industry.
Projected Growth and Size of the Retinal Biologics Market
The retinal biologics market is anticipated to experience swift…
More Releases for Pharma
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
